J&J said it “thanks Dr. Mammen for his contributions” and that William Hait, MD, PhD, will serve as the interim replacement for Dr. Mammen, who held the role for five years.
Before joining J&J, Dr. Mammen worked in executive roles at several pharmaceutical research and development companies, including Merck, Theravance Biopharma, Innoviva and Theravance, according to his LinkedIn profile.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
